Chemcon Speciality Chemicals Ltd
Incorporated in 1988, Chemcon Speciality Chemicals Ltd manufactures Pharmaceutical intermediates and Oilfield Chemicals[1]
- Market Cap ₹ 724 Cr.
- Current Price ₹ 198
- High / Low ₹ 257 / 125
- Stock P/E 24.2
- Book Value ₹ 130
- Dividend Yield 3.29 %
- ROCE 6.35 %
- ROE 4.70 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is providing a good dividend yield of 3.29%.
- Company's working capital requirements have reduced from 161 days to 108 days
Cons
- The company has delivered a poor sales growth of -0.29% over past five years.
- Company has a low return on equity of 4.61% over last 3 years.
- Earnings include an other income of Rs.15.1 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 | 97 | 88 | 158 | 303 | 262 | 243 | 257 | 303 | 267 | 207 | 240 | 265 | |
| 56 | 87 | 79 | 112 | 237 | 192 | 162 | 175 | 232 | 240 | 174 | 210 | 223 | |
| Operating Profit | 8 | 10 | 9 | 46 | 66 | 70 | 81 | 82 | 71 | 27 | 33 | 30 | 42 |
| OPM % | 12% | 10% | 10% | 29% | 22% | 27% | 33% | 32% | 23% | 10% | 16% | 13% | 16% |
| -1 | 0 | 0 | 0 | 2 | 4 | 5 | 9 | 13 | 13 | 14 | 15 | 15 | |
| Interest | 2 | 3 | 2 | 3 | 4 | 5 | 4 | 1 | 1 | 4 | 3 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 6 | 8 | 10 | 11 | 12 | 14 |
| Profit before tax | 3 | 5 | 5 | 41 | 61 | 65 | 76 | 84 | 74 | 26 | 33 | 32 | 40 |
| Tax % | 3% | 35% | 37% | 35% | 30% | 25% | 26% | 25% | 26% | 27% | 26% | 26% | |
| 3 | 3 | 3 | 26 | 43 | 49 | 56 | 63 | 55 | 19 | 24 | 24 | 30 | |
| EPS in Rs | 0.84 | 1.02 | 0.94 | 8.30 | 13.54 | 15.37 | 15.40 | 17.13 | 15.04 | 5.24 | 6.67 | 6.44 | 8.17 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 27% | 0% | 0% | 101% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 0% |
| 3 Years: | -7% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | -16% |
| 3 Years: | -25% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -14% |
| 3 Years: | -8% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 8% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 32 | 32 | 37 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 13 | 16 | 19 | 46 | 65 | 115 | 317 | 381 | 421 | 440 | 464 | 447 | 441 |
| 12 | 13 | 20 | 17 | 33 | 46 | 6 | 36 | 64 | 43 | 25 | 53 | 27 | |
| 10 | 9 | 15 | 27 | 43 | 34 | 44 | 45 | 32 | 26 | 29 | 32 | 33 | |
| Total Liabilities | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 568 | 538 |
| 20 | 19 | 24 | 30 | 40 | 49 | 67 | 82 | 141 | 146 | 149 | 195 | 190 | |
| CWIP | 0 | 0 | 0 | 0 | 1 | 4 | 9 | 34 | 14 | 42 | 40 | 21 | 21 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 | 11 |
| 24 | 27 | 38 | 67 | 133 | 173 | 328 | 382 | 398 | 356 | 355 | 342 | 316 | |
| Total Assets | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 | 568 | 538 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 5 | 10 | 14 | 11 | 12 | 65 | 74 | 13 | 12 | 38 | 42 | |
| -5 | -2 | -9 | -7 | -24 | -16 | -152 | -92 | -16 | -25 | -17 | -35 | |
| -3 | -3 | -2 | -6 | 12 | 4 | 111 | 30 | 12 | -25 | -22 | -3 | |
| Net Cash Flow | -1 | -0 | -1 | 1 | -0 | 0 | 23 | 11 | 9 | -37 | 0 | 3 |
| Free Cash Flow | 3 | 3 | 2 | 7 | -2 | -2 | 34 | 24 | -32 | -31 | 29 | 32 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 105% | 65% | 130% | 62% | 51% | 41% | 99% | 119% | 49% | 78% | 124% | 163% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 51 | 93 | 68 | 77 | 124 | 142 | 146 | 81 | 112 | 91 | 97 |
| Inventory Days | 74 | 45 | 58 | 99 | 91 | 118 | 175 | 102 | 164 | 119 | 261 | 158 |
| Days Payable | 79 | 39 | 81 | 82 | 57 | 63 | 67 | 70 | 44 | 23 | 49 | 42 |
| Cash Conversion Cycle | 47 | 57 | 70 | 86 | 111 | 179 | 250 | 177 | 201 | 208 | 303 | 212 |
| Working Capital Days | 64 | 59 | 8 | 61 | 59 | 135 | 184 | 105 | 108 | 162 | 211 | 108 |
| ROCE % | 17% | 22% | 16% | 74% | 65% | 43% | 29% | 21% | 15% | 6% | 7% | 6% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Export Revenue Share % |
|
|||||||
| Organic Chemicals Revenue Share % |
||||||||
| Sales Volume - Inorganic Chemicals (Bromides) MT |
||||||||
| Sales Volume - Organic Chemicals MT |
||||||||
| Top 10 Customer Concentration % |
||||||||
| Total Sales Volume MT |
||||||||
| Installed Capacity - Inorganic Chemicals (Bromides) MTPA |
||||||||
| Installed Capacity - Organic Chemicals MTPA |
||||||||
Extracted by Screener AI
Documents
Announcements
- Financial Results For The Quarter And Half Year Ended September 30 2026
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 24, 2026, Pursuant To Regulation 30 And 33 Of The SEBI (LODR) Regulations, 2015
- Board approved unaudited Q2 and H1 FY2026-27 results on October 24, 2026; no dividend declared.
-
Board Meeting Intimation for Under Regulation 29 Of SEBI (LODR) Regulations, 2015.
- Board meets October 24, 2026 to approve Q2 and half-year results and consider interim dividend.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
-
Closure of Trading Window
- Trading window closed from 1 October 2026 until 48 hours after Q2 FY26 results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
Concalls
-
Aug 2026PPT
-
May 2026PPT
-
Feb 2026PPT
-
Nov 2025PPT
-
Aug 2025PPT
-
May 2025PPT
-
Feb 2025PPT
-
Oct 2024PPT
-
Aug 2024PPT
-
May 2024PPT
-
Feb 2024PPT
-
Nov 2023Transcript PPT
-
Aug 2023PPT
-
May 2023PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
Business Overview:[1]
CSCL is an ISO 9001:2015 and ISO 14001:2015 certified manufacturer of silanes, pharma intermediates, agro intermediates, and oil field chemicals. It is the largest manufacturer of specialised chemicals like HMDS and CMIC, predominantly used in the pharmaceutical industry.